Zoetis Statement on the Positive Opinion for Cytopoint Adopted by the European Medicines Agency, Committee for Medicinal Products for Veterinary Use
PARSIPPANY, N.J. – Feb. 17, 2017 - We at Zoetis are pleased that the European Medicines Agency, Committee for Veterinary Products for Medicinal Use, adopted a positive opinion for Cytopoint™ at their February meeting.
Upon full approval, Cytopoint would become the first monoclonal antibody licensed for veterinary use in the European Union. It is indicated for the treatment of clinical manifestations of atopic dermatitis in dogs.
Lokivetmab, the active substance in Cytopoint, is a caninised monoclonal antibody that specifically targets canine interleukin-31, a key cytokine in canine atopic dermatitis.
We look forward to the decision of the European Commission on our application for marketing authorization of Cytopoint.
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com
+32 227468311 (o)